key: cord-0781491-yyqwbofy
authors: Oliveira, Maria Helena Santos de; Wong, Johnny; Lippi, Giuseppe; Henry, Brandon Michael
title: Analysis of clinical and demographic heterogeneity of patients dying from COVID-19 in Brazil versus China and Italy
date: 2020-05-29
journal: Braz J Infect Dis
DOI: 10.1016/j.bjid.2020.05.002
sha: cdee62202a4c15f9d33d14fcc99b9af7585ce3e1
doc_id: 781491
cord_uid: yyqwbofy

nan

required to make further conclusions, we urge clinicians to not be too quick to dismiss the seriousness of COVID-19 in young (<60 years old) and otherwise healthy patients.

To the Editor, As the outbreak of Coronavirus disease 2019 (COVID-19) has already spread around the world, 1 many countries have found themselves mostly unprepared to deal with this new disease, which has now escalated to global pandemic. 2 While there is urgent need for development of appropriate treatments and interventions, understanding the factors associated with mortality are needed to better inform clinical guidelines and public health interventions. 3, 4 Interestingly, there is a notable difference in the rate of COVID-19 mortality across countries, which merits the consideration of epidemiologists and clinicians. It should be acknowledged that actual mortality rates may vary from reported cases in each country, and though reporting practices vary, it is likely reported cases are an underestimation of true mortality. Nonetheless, in the most recent report by the World Health Organization (WHO), there is significant variability in case fatality rates (CFR) between Brazil (6.98%), China (5.50%), and Italy (13.60%). 2

The reason for such differences in CFR remains mostly undefined. It has generally been accepted that age, sex, and burden of comorbidities (i.e., lung and heart diseases, hypertension, obesity, diabetes, renal and liver failure) may have an impact on the outcome of COVID-19 disease 5 and likely influence CFR. As understanding the differences between such populations can better enable effective public health interventions, in this article we aimed to compare the clinical characteristics and patient demographics of patients dying from COVID-19 in Brazil compared to China and Italy.

Clinical and demographic data on COVID-19 mortality in Brazil, China, and Italy were extracted from the most recent official reports from each country: Brazilian Ministry of Health, 6 China Center for Disease Control and Prevention, 7 and Italian National Institute of Health, 8 respectively. To adjust for differences in age between populations, estimates of population age distribution was obtained from the United Nations (UN) World Population Ageing 2017 Report. 9 Available data described only fatal cases, therefore making it impossible to estimate risk or odds of death. This study aims to compare the main characteristics of the deceased population of each country, estimating prevalence ratios (PR) and odds ratios (OR) with their respective 95% confidence interval (95% CI), as well as associated frequency distribution (by chi-square test). A PR represents the ratio between the proportions of a specific characteristic of two samples. It can be used to indicate how different the prevalence of a variable/outcome is in one group of subjects compared to another. Statistical analysis was conducted using the R software for statistical computing (version 6.3.2) 10 and the package epiR: Tool for the Analysis of Epidemiological Data (version 1.0-14). 11 The study was carried out in accordance with the Declaration of Helsinki, under the terms of relevant local legislation.

A total of 3611 fatal COVID-19 cases from Brazil, 1023 from China, and 23,188 from Italy were finally included in our analysis (Table 1) 

While we continue to make progress in understanding the pathogenesis of COVID-19, the results of our concise analysis help elucidating a gap in our understanding of difference in mortality rates between countries. 2 Contrary to the reports of increased risk of severe COVID-19 in older patients and in those with comorbidities, 5 our results demonstrate that the deceased population in Brazil is younger and has less comorbidities, which cannot be explained by differences in population demographics alone. A potential explanation could be differences in testing and reporting by countries, as well as discrepancies in local policies, medical care access and infrastructures between young and older patients. However, a more serious implication could also be related to infection by different viral strains, as varying virulence SARS-CoV-2 is now characterized by a considerable genetic diversity which might strongly influence its interplay with human body. 12 These findings should help providing improved public health guidance and intervention. While more studies are required to make further conclusions, we urge clinicians to not be too quick to dismiss the seriousness of COVID-19 in young (<60 years old) and otherwise healthy patients.

J o u r n a l P r e -p r o o f 

Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm

COVID-19) Situation Report -101

COVID-19: what has been learned and to be learned about the novel coronavirus disease

Potential interventions for novel coronavirus in China: A systematic review

COVID-19)

Centro de Operações de Emergência em Saúde Pública 	extbar Doença pelo Coronavírus

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) -China

Caratteristiche dei pazienti deceduti positivi all'infezione da SARS-CoV-2 in Italia

World Population Ageing

R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing

EpiR: Tools for the Analysis of Epidemiological Data

Genomic characterization of a novel SARS-CoV-2